All In Biotech

Drug Trial Radar · NCT06053814

NS-050/NCNP-03 in Boys With DMD (Meteor50)

A Phase 1/2, First in Human, Multiple-dose, 2-part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-050/NCNP-03 in Boys With Duchenne Muscular Dystrophy (DMD)

Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Sep 18, 2024

Primary completion

Mar 2028

Study completion Mar 2028

Sponsor

Lead sponsor
NS Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Nippon Shinyaku Co., Ltd.
First posted
Sep 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 4 years, up to 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • NS-050/NCNP-03Drug

    NS-050/NCNP-03 solution for IV infusion.

  • PlaceboDrug

    NS-050/NCNP-03 placebo-matching solution for IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Overall Summary of Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline up to Week 24
  2. Part 1: Area Under the Plasma Concentration Versus Time Curve (AUC) of NS-050/NCNP-03Time frame: Day 1 (1st dose) for each dose level
  3. Part 1: Amount of Drug Excreted in Urine of NS-050/NCNP-03Time frame: Day 1 (1st dose) for each dose level
  4. Part 2: Change from baseline in skeletal muscle dystrophin protein by immunoblot (Western blot)Time frame: Baseline, Week25

Locations

19 sites in 5 countries. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Alberta Children's Hospital

    Calgary, Alberta, Canada

  • British Columbia Children's Hospital

    Vancouver, British Columbia, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • National Hospital Organization Nagara Medical Center

    Nagara, Gifu, Japan

  • Hyogo Medical University Hospital

    Nishinomiya, Hyōgo, Japan

  • Miyagi Children's Hospital

    Sendai, Miyagi, Japan

  • NHO Osaka Toneyama Medical Center

    Toyonaka, Osaka, Japan

  • National Center of Neurology and Psychiatry

    Kodaira, Tokyo, Japan

  • Seoul National University Hospital

    Seoul, South Korea

  • Pusan National University Yangsan Hospital

    Yangsan, Gyeongsangnam-do, South Korea

  • Ankara Bilkent City Hospital

    Ankara, Turkey (Türkiye)

  • Istanbul University

    Istanbul, Turkey (Türkiye)

  • Yeditepe University Kosuyolu Hospital

    Istanbul, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.